Publication date: Jul 02, 2024
SARS-CoV-2 can damage human placentas, leading to pregnancy complications, such as preeclampsia and premature birth. This study investigates the histopathological changes found in COVID-19-affected placentas. This study included 23 placentas from patients with active COVID-19 during delivery and 22 samples from patients without COVID-19 infection in their medical history. The samples underwent histopathological examination for pathology, such as trophoblast necrosis, signs of vessel damage, or fetal vascular malperfusion. Newborns from the research group have lower weights and Apgar scores than healthy newborns. In the COVID-19 group, calcifications and collapsed intervillous space were more frequent, and inflammation was more severe than in the healthy group. At the same time, the placenta of SARS-CoV-2-positive patients showed signs of accelerated vascular maturation. Trophoblast necrosis was found only in the placentas of the research group. The expression of CD68+ was elevated in the COVID-19 cohort, suggesting that macrophages constituted a significant part of the inflammatory infiltrate. The increase in lymphocyte B markers was associated with placental infarctions, while high levels of CD3+, specific for cytotoxic T lymphocytes, correlated with vascular injury. SARS-CoV-2 is associated with pathological changes in the placenta, including trophoblast necrosis, calcification, and accelerated villous maturation. Those changes appear to be driven by T cells and macrophages, whose increased expression reflects ongoing histiocytic intervillositis in the placenta.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Cd3 | complications |
| Fetal | COVID-19 |
| Necrosis | histopathology |
| Vascular | placenta |
| Weights | placentitis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 Infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | Causes |
| disease | MESH | pregnancy complications |
| disease | MESH | preeclampsia |
| disease | MESH | premature birth |
| disease | MESH | infection |
| disease | IDO | history |
| drug | DRUGBANK | Sulodexide |
| disease | MESH | inflammation |
| disease | VO | time |
| disease | MESH | infarctions |
| disease | MESH | Tumor |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | Pla |
| disease | MESH | complications |
| disease | MESH | pneumonia |
| disease | MESH | acute respiratory distress syndrome |
| disease | MESH | death |
| disease | MESH | infertility |
| disease | MESH | septic shock |
| disease | IDO | immune response |
| disease | IDO | immunodeficiency |
| drug | DRUGBANK | Angiotensin II |
| disease | IDO | host |
| disease | VO | pregnant women |
| disease | VO | population |
| disease | MESH | miscarriage |
| disease | MESH | asymptomatic infections |
| disease | MESH | premature aging |
| drug | DRUGBANK | Methylergometrine |
| disease | IDO | blood |
| disease | VO | protocol |
| disease | VO | manufacturer |
| drug | DRUGBANK | Formaldehyde |
| disease | VO | USA |
| drug | DRUGBANK | Ethanol |